Headquarters
LORENVEIEN 73A, OSLO, Oslo 0585, NO
OSLO, Oslo, NO
HEMISPHERIAN AS
From the company
Hemispherian is a clinical-stage pharmaceutical company developing a novel class of small molecule drugs that target the TET2 enzyme as a targeted therapy for aggressive cancers. Its lead compound GLIX1 is entering clinical development for glioblastoma. The drugs work by restoring a cancer cell's normal epigenetic complement, triggering the DNA damage response and cancer cytotoxicity, and are well tolerated in normal tissues.
Products & services offered
Capabilities 2
Facilities
Send your requirements
Quantities, certifications, and timing.